EUVIMEDEUVIMED entdecken
Übersichtsarbeit

ASK1 Signaling in Cancer: Pathogenic Driver or Therapeutic Target?

Yumna Khan, Muhammad Afzal iD, Suhas Ballal, Laxmidhar Maharana, Mudasir Maqbool, Sumel Ashique, Kavita Goyal, Rakhi Mishra iD, Haider Ali, Gaurav Gupta, Md Sadique Hussain iD

Journal of Biochemical and Molecular Toxicology · 2025-11 · 39 (11)

DOI: 10.1002/jbt.70605 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Biochemical and Molecular Toxicology, online erschienen am 10.11.2025. Verfasst von Yumna Khan und 10 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biotechnology and Genetic Engineering (Health Division), The University of Agriculture, Peshawar, Pakistan. Hauptthemen laut MEDLINE: MAP Kinase Kinase Kinase 5, Neoplasms, Signal Transduction, Neoplasm Proteins. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 199 Literaturangaben. Gefördert von: The authors received no specific funding for this work..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Apoptosis signal‐regulating kinase 1 (ASK1), an important member of the MAP kinase kinase kinase (MAP3K), has been identified as a significant modulator of cellular responses to oxidative stress, inflammatory responses, and endoplasmic reticulum stress. Structurally characterized by its thioredoxin‐binding domain, its kinase domain, and coiled‐coil structures, ASK1 relays downstream stimulation of JNK and p38 MAPK cascades. Yet, its role in cancer function is paradoxical and simultaneously serves as both a cancer inhibitor and an activator rely on cellular settings. In this article, an overview of the molecular biology of ASK1 is presented with emphasis on the elusive balance between stimulation and suppression by upstream molecules such as Trx, TRAF proteins, and ubiquitination machinery. We provide an overview of the dualistic role of ASK1 in cancer pathophysiology showing how its dysregulation leads to tumor development, metastasis, chemoresistance, or tumor suppression by pro‐apoptotic signals, respectively. An example of context‐dependent action is provided using the examples of different cancers including lung, breast, ovarian, and hepatocellular carcinoma. Moreover, we discuss new therapeutic approaches to ASK1 such as small‐molecule inhibitors, RNA therapies, and protein‐protein interaction modulation and speculate on their potential in personalized medicine. The article also deals with future opportunities in the sense of the bivalent character of ASK1 in developing context‐dependent and targeted cancer therapies. The key to unlocking the potential of ASK1 to be used as a therapeutic intervention and overcome the complications that are posed by its dualistic nature in cancer biology lie in the understanding of the complex regulatory network it forms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MAP Kinase Kinase Kinase 5NeoplasmsSignal TransductionNeoplasm ProteinsHumansAnimals

Stichwörter der Autor:innen

ASK1Oncologysignal transductiontherapeutic targetingtumor suppressor

Substanzen

MAP Kinase Kinase Kinase 5MAP3K5 protein, humanNeoplasm Proteins

Autor:innen und Institutionen

  • Institute of Biotechnology and Genetic Engineering (Health Division), The University of Agriculture, Peshawar, Pakistan.
  • Department of Pharmaceutical Sciences, Pharmacy Program, Batterjee Medical College, Jeddah, Saudi Arabia.
  • Department of Chemistry and Biochemistry, School of Sciences, JAIN (Deemed to be University), Bangalore, India.
  • Department of Pharmaceutical Sciences, Siksha'O' Anusandhan (Deemed to be University), Bhubaneswar, India.
  • Department of Pharmacology, Government Medical College Baramulla, Jammu and Kashmir, India.
  • Department of Pharmaceutical Technology, Bharat Technology, Uluberia, West Bengal, India.

ORCID-Profile: Muhammad Afzal, Rakhi Mishra, Md Sadique Hussain

Förderung

  • The authors received no specific funding for this work.

Zitieren

APA

Khan, Y., Afzal, M., Ballal, S., Maharana, L., Maqbool, M., Ashique, S., Goyal, K., Mishra, R., Ali, H., Gupta, G., & Hussain, M. S. (2025). ASK1 Signaling in Cancer: Pathogenic Driver or Therapeutic Target?. Journal of Biochemical and Molecular Toxicology, 39(11). https://doi.org/10.1002/jbt.70605

Vancouver

Khan Y, Afzal M, Ballal S, Maharana L, Maqbool M, Ashique S, et al. ASK1 Signaling in Cancer: Pathogenic Driver or Therapeutic Target?. Journal of Biochemical and Molecular Toxicology. 2025;39(11). doi:10.1002/jbt.70605

BibTeX
@article{Khan2025,
  author = {Khan, Yumna and Afzal, Muhammad and Ballal, Suhas and Maharana, Laxmidhar and Maqbool, Mudasir and Ashique, Sumel and Goyal, Kavita and Mishra, Rakhi and Ali, Haider and Gupta, Gaurav and Hussain, Md Sadique},
  title = {ASK1 Signaling in Cancer: Pathogenic Driver or Therapeutic Target?},
  journal = {Journal of Biochemical and Molecular Toxicology},
  year = {2025},
  volume = {39},
  number = {11},
  doi = {10.1002/jbt.70605}
}
Kostenlos starten →